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Abstract
Background: Microglia, the resident macrophage-like cells in the brain, regulate innate immune responses in the
CNS to protect neurons. However, excessive activation of microglia contributes to neurodegenerative diseases.
Corticosteroids are potent modulators of inflammation and mediate their effects by binding to mineralocorticoid
receptors (MR) and glucocorticoid receptors (GR). Here, the coordinated activities of GR and MR on the modulation
of the nuclear factor-κB (NF-κB) pathway in murine BV-2 microglial cells were studied.
Methods: BV-2 cells were treated with different corticosteroids in the presence or absence of MR and GR
antagonists. The impact of the glucocorticoid-activating enzyme 11β-hydroxysteroid dehydrogenase type 1
(11β-HSD1) was determined by incubating cells with 11-dehydrocorticosterone, with or without selective inhibitors.
Expression of interleukin-6 (IL-6), tumor necrosis factor receptor 2 (TNFR2), and 11β-HSD1 mRNA was analyzed by
RT-PCR and IL-6 protein expression by ELISA. NF-κB activation and translocation upon treatment with various
corticosteroids were visualized by western blotting, immunofluorescence microscopy, and translocation assays.
Results: GR and MR differentially regulate NF-κB activation and neuroinflammatory parameters in BV-2 cells. By
converting inactive 11-dehydrocorticosterone to active corticosterone, 11β-HSD1 essentially modulates the
coordinated action of GR and MR. Biphasic effects were observed for 11-dehydrocorticosterone and corticosterone,
with an MR-dependent potentiation of IL-6 and tumor necrosis factor-α (TNF-α) expression and NF-κB activation at
low/moderate concentrations and a GR-dependent suppression at high concentrations. The respective effects were
confirmed using the MR ligand aldosterone and the antagonist spironolactone as well as the GR ligand
dexamethasone and the antagonist RU-486. NF-κB activation could be blocked by spironolactone and the inhibitor
of NF-κB translocation Cay-10512. Moreover, an increased expression of TNFR2 was observed upon treatment with
11-dehydrocorticosterone and aldosterone, which was reversed by 11β-HSD1 inhibitors and/or spironolactone and
Cay-10512.
Conclusions: A tightly coordinated GR and MR activity regulates the NF-κB pathway and the control of
inflammatory mediators in microglia cells. The balance of GR and MR activity is locally modulated by the action of
11β-HSD1, which is upregulated by pro-inflammatory mediators and may represent an important feedback
mechanism involved in resolution of inflammation.
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Background
Glucocorticoids are essential for the coordinated regula-
tion of metabolic and immune responses. They are well
known due to their potent anti-inflammatory and im-
mune suppressive effects, and therefore widely used in
clinics to treat inflammatory and autoimmune diseases.
Increasing evidence indicates that endogenously occur-
ring glucocorticoids can, in some situations, stimulate
inflammation by enhancing the production of pro-
inflammatory mediators and promoting oxidative stress
[1-3]. The underlying mechanisms and the role of cor-
ticosteroid receptors are, however, not fully understood.
Glucocorticoids exert their effects mainly by activating
glucocorticoid receptors (GR) and mineralocorticoid
receptors (MR). A comparison of corticosterone binding
to MR and GR in rat hippocampal preparations revealed
a 10-fold higher affinity for MR (Kd = 0.5 nM) compared
with GR (Kd = 5.0 nM) [4,5]. Importantly, hippocampal
MR was occupied about 80% while GR was occupied
10% only if samples were taken at the nadir of the
hypothalamus-pituitary adrenal (HPA) axis diurnal
rhythm in the morning. GR binding increased at higher
corticosterone levels, suggesting that GR is activated
during stress [6,7] and potentially also at diurnal peak
levels. Differential binding by MR and GR in various
brain cells needs to be considered in order to under-
stand effects of glucocorticoids in the CNS [8-10].
In classical mineralocorticoid target tissues involved in
electrolyte and volume regulation, such as renal cortical
collecting ducts, distal colon, and salivary and sweat
glands, MR is co-expressed with 11β-hydroxysteroid
dehydrogenase 2 (11β-HSD2), which converts active
(corticosterone, cortisol) into inactive glucocorticoids
(11-dehydrocorticosterone, cortisone) [11-13]. The close
proximity of 11β-HSD2 and MR has been proposed to
prevent MR activation by glucocorticoids, thereby render-
ing specificity of the receptor to aldosterone [14]. Defi-
cient 11β-HSD2 activity has been shown to result in
sodium and water retention, causing edema formation
and hypertension [15-17]. To avoid these adverse effects
caused by excessive activation of renal and intestinal MR,
synthetic glucocorticoids selectively activating GR have
been designed and are widely used in therapy of inflam-
matory and autoimmune diseases [18,19].
Besides, MR has important functions in vascular cells,
adipocytes, osteocytes, neutrophils, dendritic cells, and
macrophage [11]. In the brain, MR plays an important
role in hippocampal neurons and in immune cells [20-
22]. Glucocorticoids are essentially involved in the
modulation of the coordinated action of monocytes,
macrophages, astrocytes, and microglia cells during in-
flammation in the brain [23]. Interestingly, in macro-
phage and microglia cells, MR and GR are co-expressed
in the presence of 11β-HSD1, which converts inactive
11-dehydrocorticosterone and cortisone into active
corticosterone and cortisol [11]. Since circulating
glucocorticoid concentrations are 100 to 1,000 times
higher than those of aldosterone, MR activity is
most likely controlled by glucocorticoids but not al-
dosterone in these cells under physiological condi-
tions [24].
So far, only few cell lines have been reported that ex-
press MR, GR, and 11β-HSD1 at sufficient levels, allow-
ing to investigate the functional interactions between the
two corticosteroid receptors and to assess the role of
11β-HSD1 in regulating their activities. In the present
study, we show that the murine microglial cell line BV-2,
which is considered to be a suitable model of microglia to
study inflammatory parameters [25], expresses MR, GR,
and 11β-HSD1. We compared the effects of the endoge-
nous glucocorticoids 11-dehydrocorticosterone (which
requires activation by 11β-HSD1) and corticosterone, the
mineralocorticoid aldosterone and the synthetic gluco-
corticoid dexamethasone on NF-κB activation and IL-6
expression in the presence or absence of MR and GR
antagonists. Moreover, the impact of pro-inflammatory
cytokines and corticosteroids on the expression of TNFR2
and 11β-HSD1 was investigated.
Methods
Materials
Fetal bovine serum (FBS) was purchased from Atlanta
Biologicals (Lawenceville, GA, USA) and other cell cul-
ture media and supplements from Invitrogen (Carlsbad,
CA, USA). Escherichia coli 0111:B4 lipopolysaccharide
(LPS), TNFα, and IL-6 were purchased from Sigma-
Aldrich (St. Louis, MO, USA), Cay-10512 was from Cay-
man Chemicals (Hamburg, Germany), [1,2-3H]-cortisone
from American Radiolabeled Chemicals (St. Louis, MO,
USA), IL-6 ELISA kit from BD Biosciences (Allschwil,
Switzerland), and the HCS kit for evaluation of NF-κB
activation (K010011) was obtained from Cellomics Ther-
moScientific (Pittsburgh, PA, USA). Antibodies against
HDAC-1, TNFR2, NF-κB subunit p65, and phosphory-
lated p65 were obtained from Cell Signaling Technology
(Danvers, MA, USA). Antibody against β-actin and goat
anti-rabbit IgG-HRP were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA, USA).
Cell culture
The immortalized mouse microglial cell line BV-2,
developed by Blasi et al. [26,27], was kindly provided by
Professor Wolfgang Sattler, University of Graz, Graz,
Austria. Cells were cultivated in RPMI-1640 medium
supplemented with 10% FBS, 2 mM glutamine, 100 μg/mL
streptomycin, 100 U/mL penicillin, 0.1 mM non-essential
amino acids, and 10 mM HEPES, pH 7.4. Prior to treat-
ment, cells were seeded in 96-well (1 × 103 cells), 24-well
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(2 × 104 cells), 12-well (5 × 105 cells), or 6-well (1 × 106
cells) plates in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented as indicated above and incubated
for 24 h at 37°C. All experiments were performed under
the permission A070126 by the Swiss Federal Department
of Environment BAFU.
Quantification of mRNA expression
Total RNA from treated cells was isolated using Trizol
reagent according to the protocol from the manufacturer
(Invitrogen). The concentration and purity of the total
RNA was assessed by a NanoDropW spectrophotometer.
A 260/280 nm absorbance ratio of 1.8 or higher was
accepted for purity of total RNA. Total RNA was used
for cDNA synthesis with oligo-dT primers and the
Superscript-III first-strand synthesis system (Invitrogen).
Total RNA (0.5 μg) and oligo-dT primers (0.5 μg) were
incubated for 5 min at 56°C, followed by addition of
4.90 μL of 5 × first strand buffer, 1.5 μL of 0.1 M dithio-
threitol (DTT), 0.5 μL of RNAse H inhibitor (50 U),
1 μL of 10 mM dNTPs, and 0.1 μL of SupersriptW Re-
verse Transcriptase III (total reaction volume 24.5 μL).
The reaction was performed for 1 h at 42°C, followed by
adding 80 μL of DEPC-treated water and storage at −20°C
until further use. Relative quantification of mRNA ex-
pression levels was performed by real-time RT-PCR
using the KAPA SYBRW FAST qPCR Kit (Kapa Biosys-
tems, Boston, MA, USA) and gene-specific oligonucleo-
tide primers. Quantitative real-time RT-PCR was
performed in a final volume of 20 μL and using a Rotor-
Gene 6000 thermal cycler (Corbett Research, Sydney,
Australia). The following amplification procedure was
applied: initial denaturation for 15 min at 95°C, followed
by 40 cycles of denaturation for 15 s at 94°C, annealing
for 30 s at 56°C, and extension for 30 s at 72°C. Three
replicates were analyzed per sample. Relative gene ex-
pression compared with the internal control GAPDH
was determined using the 2-ΔΔCT method [28]. The
oligonucleotide primers for real-time RT-PCR are listed
in Additional file 1: Table S1.
Determination of IL-6 protein expression
Cells grown in 96-well plates were treated for 24 h with
the compounds indicated, and cell-free supernatants
were collected. IL-6 protein was measured using an
ELISA kit from BD Biosciences. Briefly, a 96-well plate
was coated with capture antibody overnight at 4°C, fol-
lowed by washing five times with PBS-T (PBS containing
0.05% Tween-20). The wells were blocked with assay
diluents for 1 h and washed five times. Standards and
collected culture supernatants were added to the appro-
priate wells and samples were incubated for 2 h. After
rinsing five times with PBS-T, each well was incubated
with detection antibody for 1 h. After washing, avidin-
HRP was added for 30 min. After rinsing seven times,
each well was incubated with substrate solution for
30 min in the dark. Reaction was stopped by adding 1 M
H3PO4, and the plate was analyzed by measuring absorb-
ance at 450 nm and subtracting the values at 570 nm
using a UV-max kinetic microplate reader (Molecular
Device, Devon, UK). IL-6 protein concentrations were
calculated according to the standard curve of purified
mouse IL-6.
Determination of NF-κB localization by fluorescence
microscopy
BV-2 cells were grown on poly-L-lysine coated glass
slides in 6-well plates. Following treatment, the medium
was removed and cells were fixed and stained using
CellomicsWNF-κB p65 activation HCS kit (Cellomics
ThermoScientific, Pittsburgh, PA, USA) according to the
manufacturer’s instructions. Briefly, cells were fixed with
4% paraformaldehyde in PBS for 15 min at 25°C, washed
three times with PBS, and permeabilized with PBS con-
taining 0.5% Triton X-100 for 10 min. After three
washes with PBS and blocking with 1% fatty acid-free
bovine serum albumin for 1 h the samples were incu-
bated with rabbit polyclonal antibody against the p65
subunit of NF-κB (1:500) for 2 h at 37°C. After washing,
slides were incubated in the dark with blocking buffer
containing goat anti-rabbit IgG conjugated to Alexa
Fluor 488 and Hoechst 33342 dye for 1 h. Slides were
washed with PBS and mounted with MowiolW 4–88
antifade reagent (Hoechst, Frankfurt, Germany) on glass
slides. Cells were analyzed using a confocal laser scan-
ning microscope Olympus Fluoview FV1000. Images
were captured using a magnification of 400×. The exci-
tation and emission wavelengths were 488 nm and
510 nm, respectively.
Alternatively, cells were grown in 96-well plates, fixed
and stained using Cellomics NF-κB p65 activation HCS
reagent kit. The cells were soaked in PBS at 4°C until
imaging procedure. The assay plate was analyzed on a
Cellomics ArrayScan HCS reader. The Cytoplasm to
Nucleus Translocation BioApplication software was used
to calculate the ratio of cytoplasmic and nuclear NF-κB
intensity [29]. The average intensity of 500 objects (cells)
per well was quantified (magnification 200×). Nuclear
stain (Hoechst 33342) was in channel 1 and NF-κB was
visualized in channel 2. In channel 2 an algorithm was
utilized to identify the nucleus and surrounding cyto-
plasm in each cell; this analysis method reports the ave-
rage intensity within each nuclear mask as well as the
total of the nuclear and cytoplasmic intensity. The
results were reported as percentage of nuclear intensity
from total intensity. All treatments were performed in
triplicate.
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Preparation of whole cell lysates and cytoplasmic and
nuclear fractions
For preparation of whole cell lysates, cells grown in
6-well plates were washed twice with ice-cold PBS and
lysed in cold RIPA buffer (Sigma-Aldrich) supplemented
with protease inhibitor cocktail (Roche Diagnostics,
Rotkreuz, Switzerland). The extract was centrifuged at
10,000 × g for 15 min at 4°C to remove cell debris.
For preparation of cytoplasmic and nuclear fractions
cells were washed twice with PBS, harvested in 500 μL
PBS, followed by centrifugation at 450 × g for 5 min. Cell
pellets were washed once with PBS, transferred to 1.5-
mL tubes and pelleted again at 1,000 × g for 5 min. The
cells were lysed by gentle resuspension in 200 μL lysis
buffer containing 0.01 M DTT and protease inhibitors,
followed by incubation on ice for 15 min. IGEPAL CA-
630 solution (Sigma-Aldrich) was added at 0.6% v/v final
concentration and samples were vigorously mixed for
10 s, followed by centrifuging at 10,000 × g for 30 s.
Supernatants (cytoplasmic fractions) were transferred to
new tubes. The nuclear pellets were washed once with
100 μL PBS, pelleted at 450 × g for 5 min, and resus-
pended in 100 μL of extraction buffer containing 0.01 M
DTT and protease inhibitors. Nuclear suspension was
agitated for 30 min and centrifuged at 12,000 × g for
5 min. Nuclear fractions were frozen at −80°C and
thawed on ice to increase extraction of nuclear proteins
from the insoluble material. Nuclear samples were then
sonicated on ice three times for 5 s each to obtain the
final nuclear fractions.
Detection of protein expression
Protein concentrations were determined using the
PierceW BCA protein assay kit (Thermo Scientific)
according to the manufacturer’s instructions and bovine
serum albumin as standard. Cytoplasmic, nuclear, or
whole cell extracts (30 μg per sample) were resolved on
8% sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE). Proteins were then transferred to
0.2 μm polyvinylidene difluoride (PVDF) membranes
(Bio-Rad Laboratories, Hercules, CA, USA). Membranes
were incubated in Tris-buffered saline, pH 7.4, contain-
ing 0.1% Tween-20 (TBS-T), and supplemented with 5%
non-fat milk overnight at 4°C for blocking. The blots
were then incubated with primary antibodies against the
p65 subunit of NF-κB (1:500), the phosphorylated
form of p65 (1:500), TNFR2 (1:1,000), HDAC1 (1:1,000)
or β-actin (1:1,000) for 2 h at room temperature. After
washing with TBS-T, blots were incubated with goat
anti-rabbit IgG-horseradish peroxidase or anti-mouse
IgG-horseradish peroxidase (1:5,000) for 1 h at room
temperature. Blots were washed with TBS-T and immu-
nolabeling was visualized using enhanced chemilumines-
cence HRP substrate (Millipore, Billerica, MA, USA)
according to the manufacturer’s instructions using a
Fujifilm LAS-4000 detection system (Bucher Biotec,
Basel, Switzerland). β-actin was used as loading control
for cytoplasmic and whole cell protein extracts. HDAC1
was used as loading control for nuclear fractions.
11β-HSD1 activity measurements in intact BV-2 cells
BV-2 cells were grown in 24-well plates and treated with
20 ng/mL LPS in the presence or absence of 200 nM
cortisone for 24 h. Medium was removed and replaced
by assay medium containing 50 nM cortisone with 10
nCi [3H] cortisone as tracer. Following incubation for
12 h at 37°C, medium was collected and steroids were
extracted with ethyl acetate. The extracts were dried
under vacuum, reconstituted with methanol contain-
ing a mixture of 2 mM unlabeled cortisone and cor-
tisol, and steroids were separated in a chloroform/
methanol solvent system (9:1, v/v). The conversion of
cortisone to cortisol was determined by scintillation
counting.
Statistical analysis
The data were analyzed using one-way ANOVA (V5.00;
GraphPad Prism Software Inc., San Diego, CA, USA).
When ANOVA showed significant differences between
groups, Tukey’s post hoc test was used to determine
whether specific pairs of groups showed statistically sig-
nificant differences. P < 0.05 was considered statistically
significant.
Results
Potentiation of LPS-induced pro-inflammatory cytokine
expression by low concentrations of endogenous
glucocorticoids
To test whether the murine microglia cell line BV-2
might represent a suitable cell system to study the role
of corticosteroid receptors and local glucocorticoid acti-
vation on pro-inflammatory cytokine production, we
first determined the mRNA expression of GR, MR, and
11β-HSD1 using real-time RT-PCR. Substantial levels of
mRNA expression for all three genes were detected. Ap-
proximately 10-fold higher GR mRNA than MR mRNA
expression was obtained, in line with evidence for an
order of magnitude higher expression of GR com-
pared with MR in the kidney [30]. Thus, the expres-
sion pattern suggests that BV-2 cells can be used to
investigate mechanisms of corticosteroid-mediated modu-
lation of NF-κB activation and pro-inflammatory cytokine
expression.
BV-2 cells are sensitive to LPS, and incubation with
LPS resulted in a concentration-dependent increase in
the expression of TNF-α mRNA (Figure 1A). It is im-
portant to note that the absolute response depends on
the batch of LPS and on batch and state of BV-2 cells.
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The three independent experiments shown in Figure 1A
were performed with different batches of LPS and BV-2
cells than the three independent experiments shown in
Figure 1B. Another factor influencing the absolute
response values is the composition of the culture
medium. Performing the experiments shown in
Figure 1B in medium with charcoal-treated FBS resulted
in almost two-fold higher TNF-α mRNA expression
levels, whereby the relative expression changes were
comparable (data not shown). As shown in Figure 1B
preincubation of cells for 24 h with 25 nM cortico-
sterone, corresponding to low physiological glucocorti-
coid concentrations, resulted in a pronounced stimulation
of TNF-α expression upon treatment with LPS. Compa-
rable effects, although somewhat less efficient, were
observed when using 11-dehydrocorticosterone as sub-
strate. This suggests a pro-inflammatory effect of low en-
dogenous glucocorticoid concentrations and a role of the
Figure 1 Potentiation of LPS-induced TNF-α mRNA expression by low concentrations of corticosterone. (A) BV-2 cells were incubated
with 10, 50, and 100 ng/mL LPS for 24 h. (B) Cells were exposed to 50 nM 11-dehydrocorticosterone, which requires conversion to corticosterone
by 11β-HSD1, or 25 nM corticosterone for 24 h prior to incubation with 50 ng/mL LPS for another 24 h. TNF-α mRNA expression was measured
by real-time RT-PCR. Data (mean ± SD of three independent experiments) represent ratios of TNF-α mRNA to GAPDH control mRNA from treated
cells normalized to the values obtained from cells incubated with vehicle (DMSO). *P <0.05, ***P <0.005.
Figure 2 Inhibition of 11β-HSD1 reversed the 11-dehydrocorticosterone-dependent stimulation of LPS induced IL-6 expression.
(A, B) IL-6 mRNA expression was measured by real-time RT-PCR. Ratios of IL-6 mRNA to GAPDH control mRNA of treated cells were normalized to
values obtained from cells incubated with vehicle (DMSO). (A) BV-2 cells were treated for 24 h with LPS. (B) Cells were pretreated for 24 h with
25 nM corticosterone or with 50 nM 11-dehydrocorticosterone in the presence or absence of 1 μM of the 11β-HSD1 inhibitor T0504, followed by
incubation with 50 ng/mL LPS for an additional 24 h. (C) IL-6 protein levels were quantified by ELISA. Cells were treated for 24 h with 25 nM
corticosterone or with 50 nM 11-dehydrocorticosterone in the presence or absence of 1 μM T0504, followed by 10 ng/mL LPS for an additional
24 h. Data normalized to control represent mean ± SD from three independent experiments. *P <0.05, ***P <0.005.
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glucocorticoid-activating enzyme 11β-HSD1 in stimula-
ting inflammation.
We measured IL-6 expression as an accepted read-out
to assess the sensitivity of exposure to LPS and subse-
quent activation of NF-κB [31]. LPS induced IL-6 expres-
sion in a concentration-dependent manner (Figure 2A).
Preincubation with 25 nM corticosterone potentiated
IL-6 expression (Figure 2B). A similar stimulation of IL-6
expression was observed upon preincubation with 50 nM
11-dehydrocorticosterone, an effect which was reversed
by the two structurally distinct selective 11β-HSD1
inhibitors BNW-16 [32] (data not shown) and T0504
Figure 3 Differential modulation of IL-6 expression by MR and GR. BV-2 cells were treated with various concentrations of 11-
dehydrocorticosterone (A, B), corticosterone (A-D), dexamethasone (E, F), or aldosterone (G, H) in the presence or absence of 1 μM of MR
antagonist spironolactone (C, D, G, H) or 1 μM of GR antagonist RU-486 (C-F) for 24 h, as indicated. (A, C, G, E) Quantification of IL-6 mRNA
expression by real-time RT-PCR. Data represent ratios of IL-6 mRNA to GAPDH control mRNA from treated cells normalized to the values obtained
from cells incubated with vehicle (DMSO). (B, D, F, H) Quantification of IL-6 protein expression by ELISA. Data represent mean ± SD from three
independent experiments. **P <0.01, ***P <0.005.
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(Figure 2B, also known as Merck-544 [33,34]). The im-
pact of LPS and glucocorticoids on IL-6 protein expres-
sion was assessed by ELISA. Increased IL-6 protein was
observed upon treatment of cells with LPS, whereby the
effect on protein expression was more pronounced than
the effect on mRNA levels, suggesting enhanced transla-
tion and/or protein stability in addition to enhanced gene
expression. Importantly, both preincubation with cortico-
sterone and 11-dehydrocorticosterone further increased
IL-6 expression, whereby the effect of the latter was
blocked by 11β-HSD1 inhibitors (Figure 2C). In the ab-
sence of LPS, incubation of BV-2 cells with 25 nM
corticosterone and 50 nM 11-dehydrocorticosterone
both enhanced IL-6 expression. As expected, the effect of
11-dehydrocorticosterone was abolished by 11β-HSD1
inhibition.
MR and GR differentially modulate the IL-6 expression
Since glucocorticoids are known as potent anti-
inflammatory drugs, we next determined the concentration
dependence of IL-6 expression and compared the effects of
11-dehydrocorticosterone, corticosterone, and dexametha-
sone. The potent GR agonist dexamethasone suppressed
IL-6 mRNA and protein expression in a concentration-
dependent manner (Figure 3A, B). Unlike the GR-selective
ligand dexamethasone, 11-dehydrocorticosterone (upon
conversion to corticosterone by 11β-HSD1) showed a bi-
phasic response with peak stimulatory effects at about
50 nM and potent suppression at concentrations higher
than 250 nM. Neither spironolactone nor RU-486 at a
concentration of 1 μM inhibited 11β-HSD1 enzyme acti-
vity (measured as conversion of radiolabeled cortisone to
cortisol in cell lysates). At 20 μM, spironolactone showed
weak inhibition with 78 ± 14% remaining activity, and in
the presence of RU-486 remaining activity was 69 ± 9%,
thus excluding that the observed effects of the antagonists
on IL-6 expression were due to 11β-HSD1 inhibition. A
similar bi-phasic response, with maximal stimulation at
25 nM, was obtained using corticosterone. The stimula-
tory effect, but not the suppressive effect, could be pre-
vented by co-treatment with the MR antagonist
spironolactone (Figure 3C). The bi-phasic response to cor-
ticosterone of IL-6 expression and suppression by spir-
onolactone was confirmed on the protein level using
ELISA (Figure 3D). High corticosterone concentrations,
that is 250 nM, decreased IL-6 protein levels. The GR an-
tagonist RU-486 did not affect the corticosterone-induced
stimulation of IL-6 mRNA and protein expression. Im-
portantly, at 250 nM corticosterone, which suppressed IL-
6 expression, co-incubation with RU-486 caused an
increase in IL-6 mRNA and protein expression
(Figure 3C, D). This suggests that at higher gluco-
corticoid concentrations GR prevents MR-mediated ac-
tivation of IL-6 production and that GR blockade
results in pronounced MR-mediated stimulation of pro-
duction of pro-inflammatory cytokines. Dexamethasone
did not affect IL-6 mRNA expression at 100 nM but
resulted in a decrease at higher concentrations
(Figure 3E). Interestingly, IL-6 protein production was
significantly decreased at 100 nM dexamethasone
(Figure 3F), suggesting an inhibition of IL-6 translation
or decreased protein stability. The reason for the high
concentration of dexamethasone needed to suppress IL-6
expression remains unclear; however, since intact cells
were used, an efflux pump may be involved. As expected,
spironolactone did not affect the dexamethasone-
mediated effects (data not shown), whereas they were
reversed by RU-486 (Figure 3E, F). Opposite effects were
obtained upon incubation of BV-2 cells with the MR li-
gand aldosterone, which induced IL-6 mRNA and protein
expression, whereby these effects were fully reversed by
co-treatment with spironolactone (Figure 3G, H).
Effect of corticosteroids on IL-6 expression is mediated
through NF-κB
Next, we tested whether the stimulation of IL-6 produc-
tion by low/moderate concentrations of 11-dehydrocorti-
costerone, corticosterone, and aldosterone is dependent
on NF-κB activation. Treatment of cells with the NF-κB
translocation inhibitor Cay-10512 diminished the
corticosteroid-mediated IL-6 production (Figure 4),
suggesting that MR-dependent activation of NF-κB is
involved in the stimulation of IL-6 expression. To
visualize NF-κB activation, immune-fluorescence stain-
ing using antibody against the p65 subunit of NF-κB
was performed. As shown in Figure 5, incubation of
cells with 25 nM corticosterone or 25 nM aldosterone
enhanced the presence of p65 in the nuclei, whereby
the corticosteroid-induced NF-κB translocation could
be prevented by co-treatment with either spironolac-
tone or Cay-10512.
The MR-dependent NF-κB activation was further ana-
lyzed by determination of the distribution of p65 using
Cellomics ArrayScan high-content imaging (Figure 6).
Incubation with aldosterone enhanced the presence of
p65 in the nucleus, an effect that was blocked by spi-
ronolactone. In contrast, incubation with dexamethasone
diminished the presence of p65 in the nucleus, and
co-incubation with the GR antagonist RU-486 pre-
vented this effect. The subcellular distribution of p65
was further assessed by western blot analysis of cyto-
plasmic and nuclear fractions of BV-2 cells. Incuba-
tion of cells in the presence of corticosterone or
aldosterone led to elevated amounts of the phosphory-
lated form of p65 in the nucleus, an effect that was pre-
vented by co-treatment with spironolactone (Figure 7A)
or Cay-10512 (Figure 7B).
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Differential modulation of TNFR2 expression by
MR and GR
The sensitivity of microglia cells to pro-inflammatory
cytokines such as TNF-α is dependent, among other fac-
tors, on the expression levels of membrane surface
receptors like TNFR2 that control intracellular signaling
pathways. As observed for IL-6 expression, low/moderate
concentrations of corticosterone, that is 25 nM and
50 nM, induced TNFR2 mRNA expression but high con-
centrations of 250 nM or higher decreased its expression
(Figure 8A). The induction by low/moderate cortico-
sterone was reversed by co-treatment with the MR anta-
gonist spironolactone, whereas GR antagonist RU-486
abolished the suppressive effect of high corticosterone.
The selective GR ligand dexamethasone had an opposite
effect with a concentration-dependent suppression of
TNFR2 mRNA expression that was reversed by co-
incubation with RU-486 (Figure 8B). As observed for low
corticosterone, TNFR2 mRNA expression was induced
upon treatment with aldosterone (Figure 8C). The induc-
tion of TNFR2 expression by corticosterone (50 nM) and
aldosterone (25 nM) was confirmed on the protein level
by western blotting (Figure 8D). Moreover, we found that
the inhibitor of NF-κB translocation Cay-10512 was able
to completely abolish the induction of TNFR2 mRNA ex-
pression by IL-6, low/moderate glucocorticoids or aldos-
terone (Figure 8C). Western blotting revealed the
potentiation of TNFR2 protein expression by 50 nM
Figure 4 Blockage of corticosteroid-dependent IL-6 induction
by inhibition of NF-κB. BV-2 cells were pretreated with 250 nM of
the NF-κB inhibitor Cay-10512 for 1 h, followed by incubation with
25 nM corticosterone, 50 nM 11-dehydrocorticosterone, or
aldosterone for another 24 h. IL-6 protein was measured by ELISA.
Results represent mean ± SD from three independent experiments.
**P <0.01 and ***P <0.005.
Figure 5 Corticosterone- and aldosterone-mediated NF-κB translocation is dependent on MR. BV-2 cells were treated for 24 h with
vehicle (A), 50 ng/mL TNF-α (B), 25 nM corticosterone (C), 25 nM corticosterone and 1 μM spironolactone (D), 25 nM corticosterone and 250 nM
Cay-10512 (E), 50 nM aldosterone (F), 50 nM aldosterone and 1 μM spironolactone (G), or 50 nM aldosterone and 250 nM Cay-10512 (H). The
localization of the p65 subunit of NF-κB was visualized by immunofluorescence microscopy using a primary antibody against p65 and a
secondary ALEXA fluor 488 labeled antibody (magnification 400×).
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corticosterone and 50 nM aldosterone, and further
demonstrated the requirement of NF-κB activation for
this induction (Figure 8E). 11-dehydrocorticosterone simi-
larly induced TNFR2 expression, which was prevented by
inhibition of 11β-HSD1 (Figure 8F).
IL-6 and low glucocorticoids synergistically increased
11β-HSD1 mRNA expression and reductase activity
Glucocorticoids showed a bi-phasic effect on the pro-
duction of pro-inflammatory cytokines, depending on
activation of MR only, at low concentrations, or both
MR and GR at higher concentrations. Thus, an elevation
of the intracellular concentration of active glucocorti-
coids by 11β-HSD1 may play an important role in the
resolution of inflammation by causing a shift from MR-
to GR-mediated regulation of pro-inflammatory cytokine
expression. As shown in Figure 9, incubation of BV-2
cells with 20 ng/mL of IL-6 resulted in increased 11β-
HSD1 mRNA expression, which was strongly enhanced
by co-incubation with 50 nM 11-dehydrocorticosterone.
Pharmacological inhibition of 11β-HSD1 prevented the
effects of 11-dehydrocorticosterone. To test whether in-
cubation with IL-6 would enhance 11β-HSD1 enzyme
activity, we measured the conversion of radiolabeled cor-
tisone to cortisol. Due to technical reasons cortisone in-
stead of 11-dehydrocorticosterone was used to study the
effect on enzyme activity. Both IL-6 and cortisone
resulted in increased 11β-HSD1 reductase activity, which
was strongly enhanced by co-incubation with IL-6 and
cortisone (data not shown), indicating that the changes
observed on the mRNA level are translated to enzyme
activity.
Interestingly, while low corticosterone in the absence
of IL-6 showed weak stimulatory effects on 11β-HSD1
expression, higher concentrations resulted in a more
pronounced induction of expression (Figure 10). Spi-
ronolactone and RU-486 both were able to block the in-
duction of 11β-HSD1 expression. Both, treatment of
cells with aldosterone and dexamethasone enhanced
11β-HSD1 mRNA expression. Together with the fact
that low and high glucocorticoid concentrations led to
increased 11β-HSD1 expression, the results suggest a
feed-forward regulation including both MR and GR.
Figure 6 Differential effects of MR and GR agonists on NF-κB
translocation. BV-2 cells were treated with aldosterone or
dexamethasone in the presence or absence of 1 μM RU-486 or 1 μM
spironolactone for 24 h, followed by analysis of the intracellular
localization of p65 by Cellomics ArrayScan HCS imaging system. The
ratio between the intensity of nuclear p65 fluorescence and total
cellular p65 fluorescence was quantitated. Results represent mean ±
SD from three independent experiments. *P <0.05 and ***P <0.005.
Figure 7 Nuclear - cytoplasmic distribution of NF-κB p65 determined by western blotting. BV-2 cells were treated for 24 h with 50 ng/mL
TNF-α, 25 nM corticosterone, or 50 nM aldosterone in the absence or presence of 1 μM spironolactone or 1 μM RU-486 (A), or in the presence of
250 nM Cay-10512 (B), followed by preparation of nuclear and cytoplasmic fractions, separation of proteins by SDS-PAGE and analysis of p65
and phospho-p65 expression by western blotting. Actin served as a loading control. A representative blot from three independent
experiments is shown.
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Discussion
A recent comparison of the murine BV-2 cell line with
primary mouse microglia cells revealed highly overlap-
ping gene expression profiles upon stimulation with
LPS, although the response in BV-2 was generally less
pronounced [25]. Approximately 90% of the genes
induced by LPS in BV-2 cells were also induced in pri-
mary microglia, and 50% of the genes were also affected
in hippocampal microglia following in-vivo stimulation
of mice by intracerebroventricular LPS injection. These
observations indicate that the BV-2 cell line is a suitable
model of murine microglia to study neuroinflammatory
parameters.
In the present study, we employed BV-2 cells as a
macrophage/microglia cell model to characterize the im-
pact of endogenous and synthetic corticosteroids on NF-
κB activation and on IL-6 and TNFR2 expression. We
found that BV-2 cells functionally express MR, GR, and
11β-HSD1, and our results emphasize the importance of
a well-balanced activity of MR, which stimulates pro-
inflammatory mediators, and GR that counteracts these
effects. The selective MR ligand aldosterone exclusively
resulted in NF-κB activation and upregulation of IL-6
and TNFR2 expression, whereas the selective GR ligand
dexamethasone had opposite effects. The concentration
of aldosterone to activate MR in BV-2 cells was approxi-
mately one order of magnitude higher than anticipated
based on its Kd of about 0.5 nM. The effect on IL-6 pro-
tein levels was more pronounced than that on mRNA ex-
pression, indicating increased translation and/or protein
stability. Similar observations were made using dexa-
methasone, for which Kd values for GR of 3–4 nM have
been reported [5,35]. While 100 nM dexamethasone rea-
dily suppressed IL-6 protein it had no effect on mRNA ex-
pression. As a possible explanation an efflux pump
expressed in BV-2 cells may lower the actual intracellular
concentration of aldosterone and dexamethasone.
Corticosterone and 11-dehydrocorticosterone (upon
conversion to corticosterone by 11β-HSD1) stimulated
the expression of IL-6 and TNFR2 and activated NF-κB
at low/moderate concentrations by acting through MR,
whereas higher concentrations exerted suppressive
effects by acting through GR. Over 95% of the circula-
ting corticosterone is bound to transcortin and albumin.
Under normal conditions peak corticosterone concentra-
tions in mice and rats in the unstressed state range be-
tween 250 nM and 500 nM, thus assuming that the free
fraction in plasma reaches concentrations up to 25 nM.
Figure 8 Activation of MR but not GR enhanced TNFR2 expression by a NF-κB-dependent mechanism. BV-2 cells were treated for 24 h
with corticosterone (A, C, D, E), 11-dehydrocorticosterone (F), dexamethasone (B), or aldosterone (C-F), in the presence or absence of 1 μM
spironolactone (A, C, D), 1 μM RU-486 (A, B), or 250 nM NF-κB inhibitor Cay-10512 (C, E). The impact of 11β-HSD1 was assessed by co-incubation
of cells with 1 μM T0504. TNFR2 mRNA was quantitated by real-time RT-PCR. Data (mean ± SD from three independent experiments) represent
ratios of TNFR2 mRNA to GAPDH control mRNA from treated cells normalized to the values obtained from cells incubated with vehicle (DMSO).
For western blot analysis (D, E, F) equal protein amounts were loaded and probed for TNFR2 with actin as a loading control. A representative blot
from three independent experiments is shown. ***P <0.005.
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The intracellular concentrations may differ significantly
from this value depending on uptake and 11β-HSD-
dependent metabolism. In the presented experiments,
we used 25 nM as a low and 250 nM as a high cortico-
sterone concentration in culture medium containing
10% FBS. Despite the reduced amount of serum proteins
present in the culture medium, the capacity should be
sufficient to bind most of the 25 nM corticosterone
added, probably resulting in a free steroid concentration
below 2 nM. Nevertheless, the MR with a Kd of 0.5 nM
for corticosterone is expected to be occupied, whereas
the GR with a Kd of 5 to 10 nM is probably not acti-
vated, thus reflecting the situation under normal physio-
logical conditions. In contrast, at 250 nM the binding
capacity of the FBS present in the culture medium is
probably saturated, resulting in high unbound cortico-
sterone levels, reflecting levels reached during stress
conditions and leading to occupation of GR.
Upon further increasing corticosterone from concen-
trations needed for maximal induction of IL-6 expres-
sion, a rapid decline was observed (Figure 3A, B). This
may be explained by the higher expression levels of GR
compared with MR, suggesting that occupation of few
GR molecules may be sufficient to suppress MR activity.
It is not clear at present whether GR suppresses MR
function by competing for coactivators/corepressors, by
competing for binding sites on the promoter of a given
target gene, or by formation of heterodimers. Interest-
ingly, RU-486 enhanced IL-6 and TNFR2 expression in
the absence of added steroids (Figure 3E, Figure 8B). In
preliminary experiments using transfected cells, we
observed ligand-independent MR activity that was low-
ered upon co-expressing GR. RU-486 might act as an in-
verse agonist and induce a conformational change upon
binding to GR, which may prevent heterodimer
Figure 9 Potentiation of the IL-6-dependent increase of
11β-HSD1 mRNA expression by low concentrations of
11-dehydrocorticosterone. BV-cells were pretreated with
1 μM 11β-HSD1 inhibitor T0504 where indicated for 1 h, followed by
addition of 50 nM 11-dehydrocorticosterone with or without
20 ng/mL IL-6 and incubation for another 24 h. 11β-HSD1 mRNA
was determined by real-time RT-PCR. Data (mean ± SD from
three independent experiments) represent ratios of 11β-HSD1 mRNA
to GAPDH control mRNA from treated cells normalized to the
values obtained from cells incubated with vehicle (DMSO). **P <0.01,
***P <0.005.
Figure 10 11β-HSD1 mRNA expression is enhanced by both MR and GR activation. BV-2 cells were treated for 24 h with corticosterone (A),
aldosterone (B), or dexamethasone (C) in the presence or absence of 1 μM spironolactone (A, B) or 1 μM RU-486 (A, C). 11β-HSD1 mRNA was
quantitated by real-time RT-PCR. Data (mean ± SD from three independent experiments) represent ratios of 11β-HSD1 mRNA to GAPDH control
mRNA from treated cells normalized to the values obtained from cells incubated with vehicle (DMSO). **P <0.01, ***P <0.005.
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formation or, alternatively, GR may compete with MR
for a corepressor protein, thereby increasing MR
activity.
Nevertheless, the results suggest a tightly controlled
and coordinated action of MR and GR in the regulation
of NF-κB activity and the production of and sensitivity
to pro-inflammatory cytokines in microglia cells. Pro-
inflammatory cytokines such as TNF-α, IL-1β, and IL-6,
and subsequent activation of NF-κB, lead to elevated ex-
pression and activity of 11β-HSD1, which results in
enhanced local levels of active glucocorticoids (this
study, and [18]). The fact that both GR and MR promote
11β-HSD1 expression may represent an important feed-
forward regulation of glucocorticoid activation in order
to increase the intracellular concentration of active gluco-
corticoids and to shift the balance from an initially pre-
dominantly MR-mediated stimulation to a GR-mediated
suppression of inflammation. The enhanced local gluco-
corticoid activation may be necessary for the resolution of
inflammation. The suppression of pro-inflammatory cyto-
kines and NF-κB activity upon activation of GR should
then allow normalization of 11β-HSD1 expression and
activity.
Evidence for a stimulation of inflammatory parameters
by low to moderate glucocorticoid concentrations was
also obtained from recent experiments with murine
3 T3-L1 adipocytes [1]. Decreased adiponectin mRNA
and increased IL-6 mRNA were observed upon incuba-
tion of 3 T3-L1 adipocytes with 100 nM corticosterone
or cortisol. These effects were partially reversed by treat-
ment with the MR antagonist eplerenone but not by GR
antagonist RU486, suggesting that MR activation was re-
sponsible for the observed effects. Furthermore, 100 nM
of the glucocorticoids increased NADPH oxidase sub-
unit p22 mRNA levels and decreased catalase mRNA
levels, which were reversed by co-treatment with eplere-
none. However, the authors did not test the effects of
various concentrations, nor was the role of 11β-HSD1
addressed.
Other investigators observed elevated 11β-HSD1
mRNA and activity in 3 T3-L1 adipocytes that were
treated with LPS, TNF-α, or IL-1β [2]. Pharmacological
inhibition of 11β-HSD1 diminished the TNF-α-induced
activation of NF-κB and MAPK signaling. Their study,
however, did not assess the role of MR and the impact
of higher glucocorticoid concentrations. At high gluco-
corticoid levels, pharmacological inhibition of 11β-HSD1
might abolish GR activation, thereby promoting MR-
mediated pro-inflammatory effects. Since actual gluco-
corticoid concentrations in intact microglia cannot be
measured, it will be important to assess the effects of
11β-HSD1 inhibitors on neuroinflammation in vivo in
future studies. Nevertheless, these observations are in line
with our findings in microglia cells that low/moderate
glucocorticoid concentrations mainly act through MR,
thereby promoting inflammatory parameters.
During acute inflammation, TNF-α acts through
membrane-bound TNF-receptors on macrophage and
microglial cells, leading to activation of transcription fac-
tors such as NF-κB and AP1, which can induce a second
wave of pro-inflammatory cytokines, including TNF-α,
IL-1β and IL-6. TNFR2 is highly expressed on microglia
cells and plays an important role in the regulation of in-
nate immune response following brain injury on infec-
tion [36]. An elevated expression of TNFR2 upon MR
activation, as observed in the present study, is expected
to result in a higher sensitivity and more pronounced re-
sponse to external pro-inflammatory stimuli.
Disruption of MR- and GR-mediated regulation of
gene transcription and interaction with other transcrip-
tion factors can occur at several levels. Reduced GR ac-
tivity and/or enhanced MR activity, thus exacerbating
inflammation, may be caused by the presence of xeno-
biotics differentially modulating receptor activity, post-
translational receptor modifications, altered function of
receptor-associated proteins, or altered protein stability
Figure 11 Model for the role of MR and GR in regulating
neuroinflammation in BV-2 cells. This study suggests that MR
promotes a neuroinflammatory response mediated through NF-κB
activation, which can be blocked by activation GR. The control of
local glucocorticoid availability by 11β-HSD1 is important in
regulating the fine-tuning of the balance between MR and GR
activity. Corticosterone binds with high affinity to MR, followed by
binding to GR with lower affinity. 11β-HSD1 inhibitors (such as
T0504) block the differential effects of 11-dehydrocorticosterone on
MR and GR. IL-6 stimulated 11β-HSD1 expression, suggesting that
IL-6 is involved in a regulatory feed-forward mechanism to adjust
the local levels of active glucocorticoids and therefore the
balance between MR and GR. IL-6 and TNFR2 activation both lead to
the activation of NF-κB, and their own expression is upregulated
upon NF-κB activation.
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[30]. The pro-inflammatory cytokines TNF-α, IL-1β, and
IL-6 were shown to activate the HPA axis [37], thereby
enhancing circulating glucocorticoids and exerting sup-
pressive effects through GR activation. However, high
levels of TNF-α have been associated with glucocorticoid
resistance [38]. Upon excessive HPA activation, a down-
regulation of GR activity, probably caused by altered
phosphorylation of the receptor and reduced protein sta-
bility [38,39], with concomitant glucocorticoid resistance
has been observed, which may cause a shift from GR- to
MR-mediated glucocorticoid effects. GR blockade by ad-
ministration of RU486 or elimination of glucocorticoids
by adrenalectomy sensitized C57BL/6 mice to low-dose
TNF-α [38]. Moreover, hepatic GR-deficient mice
showed significantly higher levels of IL-6 in response to
TNF-α treatment.
Glucocorticoid-resistance represents a major problem in
chronic inflammation, including rheumatoid arthritis, ul-
cerative colitis, Crohn’s disease, atherosclerosis, cystic fibro-
sis, and chronic obstructive pulmonary disease [40]. An
impaired suppression by GR may lead to chronically
enhanced MR activity. It remains to be investigated whether
MR antagonists may prove beneficial in these diseases.
Increasing evidence indicates that neuroinflammation
contributes to neuronal degeneration and the progres-
sion of Parkinson’s disease [41,42]. Activated microglial
cells and increased expression of pro-inflammatory me-
diators have been found in the substantia nigra of
patients. Interestingly, elevated circulating cortisol levels
were measured in Parkinson’s disease patients together
with decreased GR expression in the substantia nigra
[43]. Selective ablation of GR in macrophage/microglia
exacerbated the loss of dopaminergic neurons induced
by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP),
enhanced the production of pro-inflammatory parameters,
and diminished the expression of anti-inflammatory me-
diators. Based on the findings of the present study, we
hypothesize that the potentiation of neuroinflammation
in GR-deficient states is due to an impaired balance
of pro- and anti-inflammatory mediators as a result of a
dysbalance of MR and GR activity. The role of MR in
Parkinson’s disease and whether MR antagonists may
prove useful in the treatment of this disease remain to be
investigated.
Conclusions
BV-2 cells represent a suitable microglia cell model for
studying effects of endogenous and synthetic corticoste-
roids on inflammatory parameters (Figure 11). These
cells co-express MR and GR, which differentially modu-
late NF-κB activity, the production of pro-inflammatory
cytokines and membrane-surface receptors involved in
the sensitivity to TNF-α. The availability of active en-
dogenous glucocorticoids in these cells is tightly
controlled by 11β-HSD1, whose expression and activity
is induced by pro-inflammatory cytokines and subse-
quent NF-κB activation. By enhancing intracellular con-
centrations of active glucocorticoids, 11β-HSD1 impacts
on the balanced regulation of MR- and GR-mediated
responses and may play a crucial role in resolution of in-
flammation. Impaired function of each of the three pro-
teins is expected to cause disturbed inflammation.
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